1. Home
  2. GAME vs RVPH Comparison

GAME vs RVPH Comparison

Compare GAME & RVPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo GameSquare Holdings Inc.

GAME

GameSquare Holdings Inc.

HOLD

Current Price

$0.26

Market Cap

26.6M

Sector

N/A

ML Signal

HOLD

Logo Reviva Pharmaceuticals Holdings Inc.

RVPH

Reviva Pharmaceuticals Holdings Inc.

HOLD

Current Price

$0.80

Market Cap

29.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GAME
RVPH
Founded
2011
2006
Country
United States
United States
Employees
132
14
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
26.6M
29.2M
IPO Year
2024
N/A

Fundamental Metrics

Financial Performance
Metric
GAME
RVPH
Price
$0.26
$0.80
Analyst Decision
Strong Buy
Analyst Count
0
7
Target Price
N/A
$66.67
AVG Volume (30 Days)
997.8K
2.5M
Earning Date
04-14-2026
03-30-2026
Dividend Yield
N/A
N/A
EPS Growth
37.72
N/A
EPS
N/A
N/A
Revenue
$96,198,101.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$17.89
N/A
P/E Ratio
N/A
N/A
Revenue Growth
85.00
N/A
52 Week Low
$0.26
$0.17
52 Week High
$2.87
$3.11

Technical Indicators

Market Signals
Indicator
GAME
RVPH
Relative Strength Index (RSI) 34.91 44.33
Support Level N/A $0.32
Resistance Level $0.33 N/A
Average True Range (ATR) 0.02 0.24
MACD 0.00 -0.08
Stochastic Oscillator 3.24 21.62

Price Performance

Historical Comparison
GAME
RVPH

About GAME GameSquare Holdings Inc.

GameSquare Holdings Inc is engaged in revolutionizing the way brands and game publishers connect with hard-to-reach Gen Z, Gen Alpha, and Millennial audiences. It's next generation media, entertainment, and technology helps creators and maximize their brand partners' return on investment. Its purpose-built platform provides marketing and creative services, offers data and analytics solutions, and amplifies awareness through FaZe Clan.

About RVPH Reviva Pharmaceuticals Holdings Inc.

Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease and Parkinson's disease psychosis and its other drug candidate is RP1208.

Share on Social Networks: